Bioabsorbable spacers enable high-dose pancreatic proton therapy, but severe adverse events remain
In 13 patients receiving spacer-assisted pancreatic proton therapy, 30.8% had grade 3 events and two-year local control was 38.2%.
In 13 patients receiving spacer-assisted pancreatic proton therapy, 30.8% had grade 3 events and two-year local control was 38.2%.
EXCERPT In 112 proton-treated low-grade glioma patients, 21% developed contrast-enhancing brain lesions, with modeling supporting increased periventricular and LET-dependent injury risk.
In nine-patient planning comparisons, proton CSI achieved the lowest activity-weighted marrow dose at 10.9 Gy versus 16.2–19.2 Gy with photon techniques.
Among 76 children aged three years or younger, proton therapy achieved 85.2% two-year local control, with 14.9% severe late toxicity.
In 16 sinonasal cancer planning cases, LET optimization reduced chiasm LET from 3.1 to 2.3 keV/μm while maintaining target coverage.
Across four proton plans, all 12 recalculations passed 3%/3 mm gamma, but stopping-power choices shifted distal range by up to 1.9 mm.
Conditioned medium from proton-irradiated chondrosarcoma cells reduced survival to 79% in chondrocytes and 59% in endothelial-like cells under different dose conditions.
In 74 matched pairs, deep learning-assisted proton planning showed no significant differences in early disease control or toxicity compared with manual planning.
All ten children completed upright proton therapy, including craniospinal irradiation, with no in-field progression at three months but limited long-term follow-up.
In 15 left-sided breast cancer cases, proton breath-hold reduced median heart dose from 2.1 to 0.8 Gy but increased lung exposure.
In 37 patients receiving preoperative spatially fractionated RT, major wound complications occurred in 37.5% with protons versus 38.1% with photons.
In 15 prostate nodal recurrence cases, IMPT maintained target coverage while substantially reducing kidney, bowel and integral dose compared with VMAT.
In 256 nasopharyngeal cancer patients, brain necrosis occurred in 6.3% after proton therapy versus 5.1% after photon IMRT, without a significant difference.
On 87 verification CTs, proton plans spared heart, lung, and breast dose but showed target undercoverage in six patients versus one with VMAT.
Across 29 studies and 2,385 patients, pooled optic neuropathy prevalence was 5%, with grade 4 toxicity reported in 39 patients.